Binimetinib is an Orally Active MEK1/2 Inhibitor for Cancer Research
Mitogen-activated protein kinase (MAPKs) are a family of conservative protein serine/threonine kinases that respond to a variety of extracellular stimuli and participate in gene expression, cell metabolism, proliferation, differentiation, and…